https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-28 / J Med Case Rep 2012 Dec;6:427
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-28 / J Med Case Rep 2012 Dec;6:4272012-12-28 00:00:002012-12-28 00:00:00A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-27 / BMC Cancer 2012 Dec;12:623
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-27 / BMC Cancer 2012 Dec;12:6232012-12-27 00:00:002019-02-15 08:46:31α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-17 / Int J Hyperthermia 2013;29(1):8-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-17 / Int J Hyperthermia 2013;29(1):8-162012-12-17 00:00:002012-12-17 00:00:00Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-722012-12-15 00:00:002019-02-15 08:49:50The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-832012-12-11 00:00:002012-12-11 00:00:00Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-92012-12-01 00:00:002019-02-15 08:48:38Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-01 / Curr Drug Discov Technol 2012 Dec;9(4):237-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-01 / Curr Drug Discov Technol 2012 Dec;9(4):237-552012-12-01 00:00:002019-02-15 08:59:35Immunotherapy with tumor vaccines for the treatment of malignant gliomas
